Remote loading of antibacterial drug vancomycin into albumin nanoparticles via ammonium sulfate gradient for

Naveed Ullah Khan1, Asmat Ullah2, Zaheer Ullah Khan3

  • 1Affiliated Hospital of Guangdong Medical University, Zhanjiang 524023, China; College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310012, China.

Insights

Novel albumin-templated vancomycin nanoparticles effectively treat antibiotic-resistant infections and promote wound healing. This topical nanotherapy offers a promising solution for challenging postoperative wound infections.

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Infectious Diseases

Background:

  • Postoperative wound infections caused by antibiotic-resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA) pose significant clinical challenges.
  • Biofilm formation, reduced drug efficacy, and poor penetration limit current treatments for surgical site infections.
  • Developing effective topical therapies is crucial for managing these resistant infections.

Purpose of the Study:

  • To develop albumin-templated vancomycin nanoparticles (Van@Alb NPs) for topical treatment of MRSA-infected wounds.
  • To evaluate the physicochemical properties, antibacterial efficacy, and wound healing capabilities of Van@Alb NPs.
  • To assess the biocompatibility and systemic toxicity of the developed nanotherapy.

Main Methods:

  • Albumin-templated vancomycin nanoparticles (Van@Alb NPs) were synthesized using a biomimetic mineralization process.
  • Physicochemical characterization included particle size, morphology, stability, and drug release kinetics.
  • In vitro antibacterial assays, biocompatibility tests, and in vivo wound healing models were employed.

Main Results:

  • Van@Alb NPs were successfully formulated with a hydrodynamic size of ~96 nm and uniform morphology.
  • The nanoparticles demonstrated enhanced stability, sustained drug release, and improved antibacterial efficiency against MRSA.
  • Accelerated wound closure (~90% by day 15) was observed with Van@Alb NPs, alongside confirmed biocompatibility and no systemic toxicity.

Conclusions:

  • Albumin-templated vancomycin nanoparticles represent a promising topical nanotherapy for combating antibiotic-resistant postoperative wound infections.
  • Van@Alb NPs effectively combine enhanced antibacterial action with wound healing promotion.
  • This nanotherapy holds potential for next-generation treatments addressing microbial resistance and tissue regeneration in wound care.